Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Genistein induces degradation of mutant huntingtin in fibroblasts from Huntington's disease patients.

Pierzynowska K, Gaffke L, Cyske Z, Węgrzyn G.

Metab Brain Dis. 2019 Mar 9. doi: 10.1007/s11011-019-00405-4. [Epub ahead of print]

PMID:
30850940
2.

Correction of Huntington's Disease Phenotype by Genistein-Induced Autophagy in the Cellular Model.

Pierzynowska K, Gaffke L, Hać A, Mantej J, Niedziałek N, Brokowska J, Węgrzyn G.

Neuromolecular Med. 2018 Mar;20(1):112-123. doi: 10.1007/s12017-018-8482-1. Epub 2018 Feb 12.

3.
4.

PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).

Ratovitski T, Arbez N, Stewart JC, Chighladze E, Ross CA.

Cell Cycle. 2015;14(11):1716-29. doi: 10.1080/15384101.2015.1033595.

5.

Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.

Cho IK, Yang B, Forest C, Qian L, Chan AWS.

PLoS One. 2019 Mar 21;14(3):e0214156. doi: 10.1371/journal.pone.0214156. eCollection 2019.

6.

Sulforaphane enhances proteasomal and autophagic activities in mice and is a potential therapeutic reagent for Huntington's disease.

Liu Y, Hettinger CL, Zhang D, Rezvani K, Wang X, Wang H.

J Neurochem. 2014 May;129(3):539-47. doi: 10.1111/jnc.12647. Epub 2014 Jan 18.

7.

Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.

Liu W, Chaurette J, Pfister EL, Kennington LA, Chase KO, Bullock J, Vonsattel JP, Faull RL, Macdonald D, DiFiglia M, Zamore PD, Aronin N.

J Huntingtons Dis. 2013;2(4):491-500. doi: 10.3233/JHD-130079.

PMID:
25062733
8.

Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression.

Weiss A, Träger U, Wild EJ, Grueninger S, Farmer R, Landles C, Scahill RI, Lahiri N, Haider S, Macdonald D, Frost C, Bates GP, Bilbe G, Kuhn R, Andre R, Tabrizi SJ.

J Clin Invest. 2012 Oct;122(10):3731-6. doi: 10.1172/JCI64565. Epub 2012 Sep 17.

9.

Striatal neurons directly converted from Huntington's disease patient fibroblasts recapitulate age-associated disease phenotypes.

Victor MB, Richner M, Olsen HE, Lee SW, Monteys AM, Ma C, Huh CJ, Zhang B, Davidson BL, Yang XW, Yoo AS.

Nat Neurosci. 2018 Mar;21(3):341-352. doi: 10.1038/s41593-018-0075-7. Epub 2018 Feb 5.

10.

The dynamics of early-state transcriptional changes and aggregate formation in a Huntington's disease cell model.

van Hagen M, Piebes DGE, de Leeuw WC, Vuist IM, van Roon-Mom WMC, Moerland PD, Verschure PJ.

BMC Genomics. 2017 May 12;18(1):373. doi: 10.1186/s12864-017-3745-z.

11.

Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease.

Luis-Ravelo D, Estévez-Silva H, Barroso-Chinea P, Afonso-Oramas D, Salas-Hernández J, Rodríguez-Núñez J, Acevedo-Arozena A, Marcellino D, González-Hernández T.

Exp Neurol. 2018 Jan;299(Pt A):137-147. doi: 10.1016/j.expneurol.2017.10.019. Epub 2017 Oct 19.

PMID:
29056363
12.

Atypical ubiquitination by E3 ligase WWP1 inhibits the proteasome-mediated degradation of mutant huntingtin.

Lin L, Jin Z, Tan H, Xu Q, Peng T, Li H.

Brain Res. 2016 Jul 15;1643:103-12. doi: 10.1016/j.brainres.2016.03.027. Epub 2016 Apr 21.

PMID:
27107943
13.

Mutant huntingtin expression in microglia is neither required nor sufficient to cause the Huntington's disease-like phenotype in BACHD mice.

Petkau TL, Hill A, Connolly C, Lu G, Wagner P, Kosior N, Blanco J, Leavitt BR.

Hum Mol Genet. 2019 Jan 9. doi: 10.1093/hmg/ddz009. [Epub ahead of print]

PMID:
30624705
14.

Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease.

Zhou X, Li G, Kaplan A, Gaschler MM, Zhang X, Hou Z, Jiang M, Zott R, Cremers S, Stockwell BR, Duan W.

Hum Mol Genet. 2018 May 1;27(9):1545-1555. doi: 10.1093/hmg/ddy061.

PMID:
29462355
15.
16.

Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.

Wegrzynowicz M, Bichell TJ, Soares BD, Loth MK, McGlothan JS, Mori S, Alikhan FS, Hua K, Coughlin JM, Holt HK, Jetter CS, Pomper MG, Osmand AP, Guilarte TR, Bowman AB.

J Huntingtons Dis. 2015;4(1):17-36.

17.

Soluble N-terminal fragment of mutant Huntingtin protein impairs mitochondrial axonal transport in cultured hippocampal neurons.

Tian J, Yan YP, Zhou R, Lou HF, Rong Y, Zhang BR.

Neurosci Bull. 2014 Feb;30(1):74-80. doi: 10.1007/s12264-013-1393-0. Epub 2013 Dec 21.

18.

Significantly differential diffusion of neuropathological aggregates in the brain of transgenic mice carrying N-terminal mutant huntingtin fused with green fluorescent protein.

Cheng PH, Li CL, Her LS, Chang YF, Chan AW, Chen CM, Yang SH.

Brain Struct Funct. 2013 Jan;218(1):283-94. doi: 10.1007/s00429-012-0401-x. Epub 2012 Mar 16.

PMID:
22422149
19.

Pharmacogenetic modulation of STEP improves motor and cognitive function in a mouse model of Huntington's disease.

García-Forn M, Martínez-Torres S, García-Díaz Barriga G, Alberch J, Milà M, Azkona G, Pérez-Navarro E.

Neurobiol Dis. 2018 Dec;120:88-97. doi: 10.1016/j.nbd.2018.08.024. Epub 2018 Aug 31.

PMID:
30176350
20.

DNA breakage and induction of DNA damage response proteins precede the appearance of visible mutant huntingtin aggregates.

Illuzzi J, Yerkes S, Parekh-Olmedo H, Kmiec EB.

J Neurosci Res. 2009 Feb 15;87(3):733-47. doi: 10.1002/jnr.21881.

PMID:
18831068

Supplemental Content

Support Center